Vaccine-induced aluminium allergy and long-lasting subcutaneous itching nodules
Abstract
Background: Aluminium contact dermatitis is rare even though aluminium is
frequently used in antiperspirants and sunscreens. Sensitisation to aluminium
is mostly a side effect of aluminium-adsorbed vaccines. These can also induce
long-lasting intensely itching subcutaneous nodules (granulomas) at the injection
site.
During clinical trials on an acellular aluminium-adsorbed pertussis vaccine in the
1990s in Gothenburg, Sweden, persistent itching nodules were -unexpectedly- reported in 745 of ~ 76 000 vaccinated. Contact dermatitis to aluminium was
verified by patch test in 377 children with itching nodules.
Aim: This thesis aims to study the long-term clinical prognosis of itching subcutaneous nodules and aluminium allergy in children who received an aluminium-adsorbed pertussis vaccine in a clinical trial.
Patients and Methods: All 745 vaccinated children with itching nodules in the
pertussis vaccine trial were enrolled in a long-term follow-up study (>20 years).
Results: The median duration of itching was 6.6 years. During the follow-up
time 637/745 (86%) of the participants experienced full symptom recovery. The
remaining were markedly improved. In 186 of 241 (77%) children who were
tested twice, aluminium hypersensitisation was no longer detectable. A negative
patch test was significantly correlated with loss of itching. 3-7% of the participants who received other aluminium-adsorbed vaccines later in life reported mild
and transient itching at the new injection site. The optimal compound to establish aluminium hypersensitivity could not be determined.
Conclusion and recommendations: Vaccine-induced subcutaneous itching nodules associated with aluminium allergy in infants and children can cause great
suffering and have a protracted course. However, long-term prospective studies5
show that both clinical symptoms and delayed hypersensitivity for aluminium
disappear over time. Further vaccination with aluminium-adsorbed vaccines is
safe in older children given that the original nodule has vanished and the itching
will have resolved or nearly resolved.
Parts of work
I. Gente Lidholm A, Bergfors E, Inerot A, Blomgren U, Gillstedt M, Trollfors B.
Unexpected loss of contact allergy to aluminium induced by vaccine. Contact dermatitis.
2013;68(5):286-92. ::doi::10.1111/cod.12053 II. Gente Lidholm A, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Comparison of
reactivity to a metallic disc and 2% aluminium salt in 366 children, and reproducibility
over time for 241 young adults with childhood vaccine-related aluminium contact allergy.
Contact Dermatitis 2018; Jul;79(1):26-30. ::doi::10.1111/cod.12977 III. Gente Lidholm A, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Long-term clinical
course and prognosis of vaccine-related persistent itching nodules. Manuscript submitted for publication. IV. Gente Lidholm A, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Long-term prognosis of
vaccine-induced contact allergy to aluminium - third patch-test and different test
preparations. In manuscript.
Degree
Doctor of Philosophy (Medicine)
University
University of Gothenburg. Sahlgrenska Academy
Institution
Institute of Clinical Sciences. Department of Dermatology and Venereology
Disputation
Torsdagen den 2 december 2021, kl 9.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg
Date of defence
2021-12-02
anette.gente.lidholm@gu.se
Date
2021-11-09Author
Gente Lidholm, Anette
Keywords
Childhood vaccine
Adverse event
Aluminium
Aluminium allergy
Itching nodules
Subcutaneous granulomas
Patch test
Tolerance
Publication type
Doctoral thesis
ISBN
978-91-8009-494-8 (PRINT)
978-91-8009-495-5 (PDF)
Language
eng